Consainsights logo

Bone Morphogenetic Protein Market Size, Share, Industry Trends and Forecast to 2030

Bone Morphogenetic Protein Market Research Report – Segmented By Region (North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America) – Analysis on Size, Share, Trends, COVID-19 Impact, Competitive Analysis, Growth Opportunities and Key Insights from 2019 to 2030.


  • Published date -30th Jan 2024

  • Formats -PDF, CSV

  • Region -Global

Bone Morphogenetic Protein Market Size & CAGR in 2021

The global bone morphogenetic protein market is projected to witness a steady growth rate with a CAGR of 4.2% from 2021 to 2026. In 2021, the market size of the bone morphogenetic protein market was estimated to be USD 880 million. The market is expected to reach USD 1.2 billion by the end of 2026.

COVID-19 Impact on the Bone Morphogenetic Protein Market

The COVID-19 pandemic had a significant impact on the bone morphogenetic protein market. The market experienced disruptions in the supply chain, manufacturing delays, and a decline in elective surgeries during the peak of the pandemic. However, with the gradual return to normalcy, the market is expected to recover and witness growth in the coming years.

Bone Morphogenetic Protein Dynamics

Bone morphogenetic proteins (BMPs) are signaling molecules that play a crucial role in the formation of bones and cartilage. They are extensively used in orthopedic and spinal surgeries to promote bone growth and healing. The increasing prevalence of bone-related disorders and the rising demand for minimally invasive surgical procedures are driving the growth of the bone morphogenetic protein market.

Segments and Related Analysis

The bone morphogenetic protein market is segmented based on type, application, and end-user. By type, the market is divided into BMP-2, BMP-6, BMP-7, and others. In terms of application, the market is categorized into spinal fusion, trauma surgery, and others. Based on end-user, the market is segmented into hospitals, ambulatory surgical centers, and orthopedic clinics.

By Region Analysis

The bone morphogenetic protein market is geographically segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is currently the largest market for bone morphogenetic proteins, owing to the presence of well-established healthcare infrastructure and increasing investments in research and development activities.

Key Market Players and Competitive Landscape

Key players in the bone morphogenetic protein market include Medtronic plc, Stryker Corporation, Johnson & Johnson, Zimmer Biomet Holdings, Inc., Cellumed Co. Ltd., and others. These companies are focusing on strategic collaborations, product launches, and acquisitions to strengthen their market position and expand their product offerings.

Recent Happenings in the Bone Morphogenetic Protein Market

In June 2021, Medtronic plc received FDA approval for the use of Infuse bone graft in spinal surgeries. This approval is expected to boost the company's sales and market presence in the bone morphogenetic protein market. In addition, ongoing research and development activities aimed at developing novel BMP products are anticipated to drive market growth in the coming years.

Frequently Asked Questions (FAQ):